Investor Stock List
Ranked #5,678 of 8,699 institutional investors

Pivotal bioVenture Partners Investment Advisor LLC

San Francisco, CA

$233M
US stock portfolio at live prices · today −$5.2M (−2.18%)
Live prices, last trade 12:52 PM ET
Value at quarter end (Q3 2026)
$252M
Change from Q2 2026
−$56.0M (−18.20%)
Positions
13 · 2 new, 1 sold out
Filed
Nov 13, 2026

Not counted in the ranking: none$15.5M of holdings we could not match to a US listing are included at their reported quarter-end value.

Holdings

Q3 2026 13F, live prices
PCVX 34.4%ARQT 11.6%AVLN 10.7%TRVI 10.0%EVMN 5.83%
StockSharesValue, live% of portfoliovs Q2 2026
PCVX Vaxcyte, Inc.1,425,470$80.2M34.4%Unchanged
ARQT Arcutis Biotherapeutics, Inc.1,008,174$26.9M11.6%Reduced −20%
AVLN Avalyn Pharma Inc.866,792$24.9M10.7%Reduced −10%
TRVI Trevi Therapeutics, Inc.1,742,672$23.4M10.0%Unchanged
EVMN Evommune Inc1,926,943$13.6M5.83%Unchanged
IMNM Immunome, Inc.732,512$11.7M5.03%Unchanged
OBX Obsidian Therapeutics, Inc.860,343$10.2M4.40%New
BRVE Braveheart Bio, Inc.317,351$6.4M2.73%New
ZBIO Zenas BioPharma, Inc.233,176$5.9M2.54%Reduced −52%
RLYB Rallybio Corporation300,579$4.6M1.96%Unchanged
MPLT MapLight Therapeutics, Inc.611,446$3.7M1.61%Unchanged
AVTX Avalo Therapeutics, Inc.434,033$2.9M1.26%Unchanged
BIOA BioAge Labs, Inc.653,374$2.9M1.23%Unchanged

Sold out in Q3 2026

StockShares held at Q2 2026Worth today
RXRX Recursion Pharmaceuticals, Inc.595,518$1.5M